India’s pharmaceutical giant Zydus Lifesciences claims to have received final approval from the Food and Drug Administration (FDA) of the United States to sell 40 mg and 80 mg of Febuxostat tablets.
According to Zydus Lifesciences, Febuxostat tablets are meant to lower hyperuricemia, or high blood uric acid, in people with gout who have been treated with allopurinol but it didn’t work well or can’t be used anymore.
Zydus Lifesciences added that the medication would be produced at the formulation manufacturing facility of the group in Moraiya, Ahmedabad, India. A drug called allopurinol is used to lower the amount of uric acid in the blood.
According to the data, annual sales of Febuxostat tablets in the United States totaled 32 million USD. Over 431 abbreviated new drug applications (ANDAs) have been submitted thus far, and the group has received 340 approvals.
Zydus Lifesciences, formerly Cadila Healthcare, is a leading Indian pharmaceutical company that offers comprehensive global health care. It has strong capabilities across the entire pharmaceutical value chain thanks to its extensive healthcare domain expertise.
